Neurodegenerative diseases share symptoms in the early stages which can delay diagnosis and treatment.
Mild-cognitive impairment (MCI) is the stage prior to Alzheimer’s Disease where an individual may experience noticeable memory loss but not enough to interfere with daily life.
Up to 80% of patients with MCI may eventually convert to Alzheimer’s, while some individuals remain stable or even revert to normal cognition.
This stage between MCI and conversion to Alzheimer’s Disease represents a treatment window where it might be possible to prevent progression to Alzheimer’s. We have been exploring this in a Phase IIa clinical trial for MCI using L-serine-rich jellybeans as the treatment. The trial is being conducted under the guidance of expert neurologists at the Houston Methodist Hospital, in Texas, and is double-blinded meaning neither the patients nor the physicians know which treatment they are on – the L-serine or placebo jellybeans. The last patient for this trial has been enrolled and data are expected in 2027.
There are currently several tests available to patients for the diagnosis of Alzheimer’s Disease from a blood draw that measure levels of the Alzheimer’s-associated toxic proteins, tau and amyloid beta. However, whether these proteins are a symptom of Alzheimer’s or cause the disease is the subject of debate and remains controversial.
At Brain Chemistry Labs, we are interested in what causes these proteins to become dysfunctional, so we are looking at mechanisms upstream of tau and amyloid beta accumulation. Think of the proteins like a “train wreck” - we are looking at the switches further up the track to try to determine what caused the crash. In this example, the switches are miRNA, which represent the earliest signal of change along the path.
Much like our ALS Test, the Alzheimer’s Disease test is based on a unique fingerprint of miRNAs that can differentiate with a high degree of accuracy plasma from patients with Alzheimer’s, MCI or healthy participants. Our Alzheimer’s biomarker will follow the same CLIA/CAP validation path as the ALS test, and we hope to have it available for medical professionals to order for patients in the coming years.
Simultaneously, we are working on a biomarker test that measures levels of a blood metabolite which is elevated in patients with MCI and increases further in patients transitioning to Alzheimer’s. This test is complementary to our miRNA biomarker test with the aim of being available to medical professionals in the coming years.
Phase IIa
L-serine for MCI, double-blinded, under the guidance of neurologists at Houston Methodist Hospital. The last patient has been enrolled; data are expected in 2027.
- TreatmentL-serine jellybeans
- PartnerHouston Methodist
- Data expected2027
- Blood testsmiRNA, metabolite
